← Back to headlines
NorthStrive Biosciences to Test Muscle-Loss Drugs in Microgravity Spaceflight
PMGC Holdings announced a term sheet with Orbit2Orbit to conduct a spaceflight study on NorthStrive’s EL-22 and EL-32 assets targeting microgravity-induced muscle atrophy.
25 Aug, 11:30 — 25 Aug, 11:30
Related Stories
Rockstar Unveils New Grand Theft Auto VI Gameplay Details Ahead of Gamescom
27m ago
Meta’s $17 Billion Settlement Draws Global Calls for Child Safety Regulations
28m ago
Trump Administration Considers New Tariffs on Semiconductor Imports
48m ago
Tech Giants Urge Global Action Against AI-Powered Cyber Threats
1h ago